New molecular insights in diabetic nephropathy

International Urology and Nephrology

Volumn 48, Issue 3, 2016, Pages 373-387

  Checheriţă, Ionel Alexandru ^a,b,c   Manda, Gina ^c   Hinescu, Mihai Eugen ^a,c   Peride, Ileana ^a,b   Niculae, Andrei ^a,b   Bîlha, Ştefana ^d,e   Grămăticu, Angelica ^d,e   Voroneanu, Luminiţa ^d,e   Covic, Adrian ^d,e  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b St John Clinical Hospital   (Romania)

^c VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^d GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e Department of Nephrology   (Romania)

Author keywords

Diabetic nephropathy; Inflammation; Oxidative stress; Prognosis; Therapy

Indexed keywords

2 ISOPROPYLIDENEHYDRAZONO 4 OXO 5 THIAZOLIDINYLACETANILIDE; ADVANCED GLYCATION END PRODUCT; ALAGEBRIUM; AMINOGUANIDINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLITAZONE DERIVATIVE; HEXOSAMINE; IMIDAPRIL; INTERLEUKIN 1; INTERLEUKIN 23; IRBESARTAN; LISINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; POLYOL; PROTEIN KINASE C; PYRIDOXAMINE; RAMIPRIL; REACTIVE OXYGEN METABOLITE; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; BIOLOGICAL MARKER;

ANTIOXIDANT ACTIVITY; CYTOKINE PRODUCTION; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DISEASE COURSE; DYSLIPIDEMIA; END STAGE RENAL DISEASE; HUMAN; HYPERGLYCEMIA; INFLAMMATION; KIDNEY FIBROSIS; LIPID PEROXIDATION; OXIDATIVE STRESS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SYSTEMATIC REVIEW; METABOLISM; PROGNOSIS;

BIOMARKERS; DIABETIC NEPHROPATHIES; HUMANS; OXIDATIVE STRESS; PROGNOSIS;

EID: 84959149360     PISSN: 03011623     EISSN: 15732584     Source Type: Journal    
DOI: 10.1007/s11255-015-1203-x     Document Type: Review

References (224)

1. Montero RM, Covic A, Gnudi L, Goldsmith D (2015) Diabetic nephropathy: What does the future hold? Int Urol Nephrol [Epub ahead of print]
2. Fabrizi F, Messa P, Martin P (2014) The unravelled link between chronic kidney disease and hepatitis C infection. New J Sci 2014:180203. doi:10.1155/2014/1802031
3. Centers for Disease Control and Prevention (CDC) (2007) Prevalence of chronic kidney disease and associated risk factors—United States, 1999–-2004. MMWR Morb Mortal Wkly Rep 56(8):161–165
4. Saran R, Li Y, Robinson B, Ayanian J, Balkrishnan R, Bragg-Gresham J, Chen JT, Cope E, Gipson D, He K, Herman W, Heung M, Hirth RA, Jacobsen SS, Kalantar-Zadeh K, Kovesdy CP, Leichtman AB, Lu Y, Molnar MZ, Morgenstern H, Nallamothu B, O’Hare AM, Pisoni R, Plattner B, Port FK, Rao P, Rhee CM, Schaubel DE, Selewski DT, Shahinian V, Sim JJ, Song P, Streja E, Kurella Tamura M, Tentori F, Eggers PW, Agodoa LY, Abbott KC (2015). US renal data system 2014 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis 66(1 Suppl 1):Svii, S1–305
5. http://www.usrds.org/2015/view/v2_01.aspx. Accessed Nov 2015
6. National Kidney Foundation (2012) KDOQI clinical practice guideline for diabetes and CKD: 2012 update. Am J Kidney Dis 60(5):850–886
7. Bakris GL (2014) Overview of diabetic nephropathy. UpToDate. http://www.uptodate.com/contents/overview-of-diabetic-nephropathy.com. Accessed Nov 2015
8. Ritz E (2007) Pathogenesis, clinical manifestations, and natural history of diabetic nephropathy. In: Feehally J, Floege J, Johnson RJ (eds) Comprehensive clinical nephrology, 3rd edn. Mosby Elsevier, Philadelphia, pp 353–364
9. Mogensen CE, Christensen CK, Vittinghus E (1983) The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 32(Suppl 2):64–78
10. Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, Joh K, Noël LH, Radhakrishnan J, Seshan SV, Bajema IM, Bruijn JA, Renal Pathology Society (2010) Pathologic classification of diabetic nephropathy. J Am Soc Nephrol 21(4):556–563
11. Katz A, Caramori ML, Sisson-Ross S, Groppoli T, Basgen JM, Mauer M (2002) An increase in the cell component of the cortical interstitium antedates interstitial fibrosis in type 1 diabetic patients. Kidney Int 61(6):2058–2066
12. Gilbert RE, Cooper ME (1999) The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int 56(5):1627–1637
13. Vashistha H, Meggs L (2013) Diabetic nephropathy: lessons from the mouse. Ochsner J 13(1):140–146
14. Kakoki M, Takahashi N, Jennette JC, Smithies O (2004) Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101(36):13302–13305
15. Kakoki M, Kizer CM, Yi X, Takahashi N, Kim HS, Bagnell CR, Edgell CJ, Maeda N, Jennette JC, Smithies O (2006) Senescence-associated phenotypes in Akita diabetic mice are enhanced by absence of bradykinin B2 receptors. J Clin Investig 116(5):1302–1309
16. Kakoki M, McGarrah RW, Kim HS, Smithies O (2007) Bradykinin B1 and B2 receptors both have protective roles in renal ischemia/reperfusion injury. Proc Natl Acad Sci USA 104(18):7576–7581
17. Brownlee M (2005) The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54(6):1615–1625
18. Lee HB, Yu MR, Yang Y, Jiang Z, Ha H (2003) Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 14(8 Suppl 3):S241–S245
19. Li JM, Shah AM (2003) ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 14(8 Suppl 3):S221–S226
20. Mima A (2013) Inflammation and oxidative stress in diabetic nephropathy: new insights on its inhibitions as new therapeutic targets. J Diabetes Res 2013:248563
21. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, Kasai K (2000) Possible relationship of monocyte chemoattractant protein-1 with diabetic nephropathy. Kidney Int 58(2):684–690
22. Sassy-Prigent C, Heudes D, Mandet C, Bélair MF, Michel O, Perdereau B, Bariéty J, Bruneval P (2000) Early glomerular macrophage recruitment in streptozotocin-induced diabetic rats. Diabetes 49(3):466–475
23. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H (2003) Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52(10):2586–2593
24. Chow F, Ozols E, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in mouse type 2 diabetic nephropathy: correlation with diabetic state and progressive renal injury. Kidney Int 65(1):116–128
25. Gaede P, Poulsen HE, Parving HH, Pedersen O (2001) Double-blind, randomised study of the effect of combined treatment with vitamin C and E on albuminuria in Type 2 diabetic patients. Diabet Med 18(9):756–760
26. Locatelli F, Canaud B, Eckardt KU, Stenvinkel P, Wanner C, Zoccali C (2003) Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant 18(7):1272–1280
27. Sies H (1997) Oxidative stress: oxidants and antioxidants. Exp Physiol 82(2):291–295
28. Ha H, Hwang IA, Park JH, Lee HB (2008) Role of reactive oxygen species in the pathogenesis of diabetic nephropathy. Diabetes Res Clin Pract 82(Suppl 1):S42–S45
29. Rösen P, Nawroth PP, King G, Möller W, Tritschler HJ, Packer L (2001) The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 17(3):189–212
30. Giugliano D, Ceriello A, Paolisso G (1996) Oxidative stress and diabetic vascular complications. Diabetes Care 19(3):257–267
31. Duckworth WC (2001) Hyperglycemia and cardiovascular disease. Curr Atheroscler Rep 3(5):383–391
32. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87(1):245–313
33. Sedeek M, Nasrallah R, Touyz RM, Hébert RL (2013) NADPH oxidases, reactive oxygen species, and the kidney: friend and foe. J Am Soc Nephrol 24(10):1512–1518
34. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hébert RL (2010) Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Ren Physiol 299(6):F1348–F1358
35. Fukuda M, Nakamura T, Kataoka K, Nako H, Tokutomi Y, Dong YF, Ogawa H, Kim-Mitsuyama S (2010) Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens 28(2):340–352
36. Sun YM, Su Y, Li J, Wang LF (2013) Recent advances in understanding the biochemical and molecular mechanism of diabetic nephropathy. Biochem Biophys Res Commun 433(4):359–361
37. Giacco F, Brownlee M (2010) Oxidative stress and diabetic complications. Circ Res 107(9):1058–1070
38. Cave AC, Brewer AC, Narayanapanicker A, Ray R, Grieve DJ, Walker S, Shah AM (2006) NADPH oxidases in cardiovascular health and disease. Antioxid Redox Signal 8(5–6):691–728
39. Konior A, Schramm A, Czesnikiewicz-Guzik M, Guzik TJ (2014) NADPH oxidases in vascular pathology. Antioxid Redox Signal 20(17):2794–2814
40. Hsu YC, Lei CC, Ho C, Shih YH, Lin CL (2015) Potential biomarkers associated with diabetic glomerulopathy through proteomics. Ren Fail 37(8):1308–1315
41. Butterfield DA, Dalle-Donne I (2014) Redox proteomics: from protein modifications to cellular dysfunction and disease. Mass Spectrom Rev 33(1):1–6
42. Butterfield DA, Dalle-Donne I (2012) Redox proteomics. Antioxid Redox Signal 17(11):1487–1489
43. Sheehan D, Rainville LC, Tyther R, McDonagh B (2012) Redox proteomics in study of kidney-associated hypertension: new insights to old diseases. Antioxid Redox Signal 17(11):1560–1570
44. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23(5):599–622
45. Lin N, Zhang H, Su Q (2012) Advanced glycation end-products induce injury to pancreatic beta cells through oxidative stress. Diabetes Metab 38(3):250–257
46. Brownlee M, Cerami A, Vlassara H (1988) Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318(20):1315–1321
47. Galler A, Müller G, Schinzel R, Kratzsch J, Kiess W, Münch G (2003) Impact of metabolic control and serum lipids on the concentration of advanced glycation end products in the serum of children and adolescents with type 1 diabetes, as determined by fluorescence spectroscopy and nepsilon-(carboxymethyl)lysine ELISA. Diabetes Care 26(9):2609–2615
48. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M (1994) Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91(24):11704–11708
49. Lu M, Kuroki M, Amano S, Tolentino M, Keough K, Kim I, Bucala R, Adamis AP (1998) Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Investig 101(6):1219–1224
50. Tufro A, Veron D (2012) VEGF and podocytes in diabetic nephropathy. Semin Nephrol 32(4):385–393
51. Galkina E, Ley K (2006) Leukocyte recruitment and vascular injury in diabetic nephropathy. J Am Soc Nephrol 17(2):368–377
52. Imani F, Horii Y, Suthanthiran M, Skolnik EY, Makita Z, Sharma V, Sehajpal P, Vlassara H (1993) Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: role in tissue remodeling. J Exp Med 178(6):2165–2172
53. Wu CC, Chen JS, Lu KC, Chen CC, Lin SH, Chu P, Sytwu HK, Lin YF (2010) Aberrant cytokines/chemokines production correlate with proteinuria in patients with overt diabetic nephropathy. Clin Chim Acta 411(9–10):700–704
54. Glogowski EA, Tsiani E, Zhou X, Fantus IG, Whiteside C (1999) High glucose alters the response of mesangial cell protein kinase C isoforms to endothelin-1. Kidney Int 55(2):486–499
55. Kanwar YS, Wada J, Sun L, Xie P, Wallner EI, Chen S, Chugh S, Danesh FR (2008) Diabetic nephropathy: mechanisms of renal disease progression. Exp Biol Med 233(1):4–11
56. Singh SB, Malamas MS, Hohman TC, Nilakantan R, Carper DA, Kitchen D (2000) Molecular modeling of the aldose reductase-inhibitor complex based on the X-ray crystal structure and studies with single-site-directed mutants. J Med Chem 43(6):1062–1070
57. James LR, Tang D, Ingram A, Ly H, Thai K, Cai L, Scholey JW (2002) Flux through the hexosamine pathway is a determinant of nuclear factor kappaB-dependent promoter activation. Diabetes 51(4):1146–1156
58. Hebert LF Jr, Daniels MC, Zhou J, Crook ED, Turner RL, Simmons ST, Neidigh JL, Zhu JS, Baron AD, McClain DA (1996) Overexpression of glutamine:fructose-6-phosphate amidotransferase in transgenic mice leads to insulin resistance. J Clin Investig 98(4):930–936
59. Tang J, Neidigh JL, Cooksey RC, McClain DA (2000) Transgenic mice with increased hexosamine flux specifically targeted to beta-cells exhibit hyperinsulinemia and peripheral insulin resistance. Diabetes 49(9):1492–1499
60. Veerababu G, Tang J, Hoffman RT, Daniels MC, Hebert LF Jr, Crook ED, Cooksey RC, McClain DA (2000) Overexpression of glutamine: fructose-6-phosphate amidotransferase in the liver of transgenic mice results in enhanced glycogen storage, hyperlipidemia, obesity, and impaired glucose tolerance. Diabetes 49(12):2070–2078
61. Leung KK, Leung PS (2008) Effects of hyperglycemia on angiotensin II receptor type 1 expression and insulin secretion in an INS-1E pancreatic beta-cell line. JOP. 9(3):290–299
62. Singh R, Alavi N, Singh AK, Leehey DJ (1999) Role of angiotensin II in glucose-induced inhibition of mesangial matrix degradation. Diabetes 48(10):2066–2073
63. Waanders F, Visser FW, Gans RO (2013) Current concepts in the management of diabetic nephropathy. Neth J Med 71(9):448–458
64. Singh R, Singh AK, Alavi N, Leehey DJ (2003) Mechanism of increased angiotensin II levels in glomerular mesangial cells cultured in high glucose. J Am Soc Nephrol 14(4):873–880
65. Kagami S, Border WA, Miller DE, Noble NA (1994) Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Investig 93(6):2431–2437
66. Kagami S, Kuhara T, Okada K, Kuroda Y, Border WA, Noble NA (1997) Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 51(3):664–671
67. Wilson HM, Haites NE, Booth NA (1997) Effect of angiotensin II on plasminogen activator inhibitor-1 production by cultured human mesangial cells. Nephron 77(2):197–204
68. Giacchetti G, Sechi LA, Rilli S, Carey RM (2005) The renin–angiotensin–aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab 16(3):120–126
69. Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G, Egido J (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21(1):16–20
70. Badshah II, Baines DL, Dockrell ME (2014) Erk5 is a mediator to TGFβ1-induced loss of phenotype and function in human podocytes. Front Pharmacol 5:71
71. Khalil N (1999) TGF-beta: from latent to active. Microbes Infect 1(15):1255–1263
72. Reeves WB, Andreoli TE (2000) Transforming growth factor beta contributes to progressive diabetic nephropathy. Proc Natl Acad Sci USA 97(14):7667–7669
73. Goldfarb S, Ziyadeh FN (2001) TGF-beta: a crucial component of the pathogenesis of diabetic nephropathy. Trans Am Clin Climatol Assoc 112:27–32
74. Siegel PM, Massagué J (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3(11):807–821
75. Chuang PY, He JC (2009) Signaling in regulation of podocyte phenotypes. Nephron Physiol 111(2):p9–p15
76. Huang F, Chen YG (2012) Regulation of TGF-β receptor activity. Cell Biosci 2:9
77. Suzaki Y, Yoshizumi M, Kagami S, Nishiyama A, Ozawa Y, Kyaw M, Izawa Y, Kanematsu Y, Tsuchiya K, Tamaki T (2004) BMK1 is activated in glomeruli of diabetic rats and in mesangial cells by high glucose conditions. Kidney Int 65(5):1749–1760
78. Browne JA, Pearson AL, Zahr RA, Niculescu-Duvaz I, Baines DL, Dockrell ME (2008) TGF-beta activates ERK5 in human renal epithelial cells. Biochem Biophys Res Commun 373(3):440–444
79. Dorado F, Velasco S, Esparís-Ogando A, Pericacho M, Pandiella A, Silva J, López-Novoa JM, Rodríguez-Barbero A (2008) The mitogen-activated protein kinase Erk5 mediates human mesangial cell activation. Nephrol Dial Transplant 23(11):3403–3411
80. Stadler K, Goldberg IJ, Susztak K (2015) The evolving understanding of the contribution of lipid metabolism to diabetic kidney disease. Curr Diabetes Rep 15(7):40
81. Jiang T, Wang Z, Proctor G, Moskowitz S, Liebman SE, Rogers T, Lucia MS, Li J, Levi M (2005) Diet-induced obesity in C57BL/6J mice causes increased renal lipid accumulation and glomerulosclerosis via a sterol regulatory element-binding protein-1c-dependent pathway. J Biol Chem 280(37):32317–32325
82. Wang W, He B, Shi W, Liang X, Ma J, Shan Z, Hu Z, Danesh FR (2012) Deletion of scavenger receptor A protects mice from progressive nephropathy independent of lipid control during diet-induced hyperlipidemia. Kidney Int 81(10):1002–1014
83. Weinberg JM (2006) Lipotoxicity. Kidney Int 70(9):1560–1566
84. Kimmelstiel P, Wilson C (1936) Intercapillary lesions in the glomeruli of the kidney. Am J Pathol 12(1):83–98.7
85. Chajek T, Stein O, Stein Y (1977) Pre- and post-natal development of lipoprotein lipase and hepatic triglyceride hydrolase activity in rat tissues. Atherosclerosis. 26(4):549–561
86. Goldberg IJ, Soprano DR, Wyatt ML, Vanni TM, Kirchgessner TG, Schotz MC (1989) Localization of lipoprotein lipase mRNA in selected rat tissues. J Lipid Res 30(10):1569–1577
87. Coburn CT, Knapp FF Jr, Febbraio M, Beets AL, Silverstein RL, Abumrad NA (2000) Defective uptake and utilization of long chain fatty acids in muscle and adipose tissues of CD36 knockout mice. J Biol Chem 275(42):32523–32529
88. Arici M, Brown J, Williams M, Harris KP, Walls J, Brunskill NJ (2002) Fatty acids carried on albumin modulate proximal tubular cell fibronectin production: a role for protein kinase C. Nephrol Dial Transplant 17(10):1751–1757
89. Thomas ME, Harris KP, Walls J, Furness PN, Brunskill NJ (2002) Fatty acids exacerbate tubulointerstitial injury in protein-overload proteinuria. Am J Physiol Ren Physiol 283(4):F640–F647
90. Ruggiero C, Elks CM, Kruger C, Cleland E, Addison K, Noland RC, Stadler K (2014) Albumin-bound fatty acids but not albumin itself alter redox balance in tubular epithelial cells and induce a peroxidemediated redox-sensitive apoptosis. Am J Physiol Ren Physiol 306(8):F896–F906
91. Sun L, Halaihel N, Zhang W, Rogers T, Levi M (2002) Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus. J Biol Chem 277(21):18919–18927
92. Wang Z, Jiang T, Li J, Proctor G, McManaman JL, Lucia S, Chua S, Levi M (2005) Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 54(8):2328–2335
93. Jiang T, Liebman SE, Lucia MS, Li J, Levi M (2005) Role of altered renal lipid metabolism and the sterol regulatory element binding proteins in the pathogenesis of age-related renal disease. Kidney Int 68(6):2608–2620
94. Muoio DM, Noland RC, Kovalik JP, Seiler SE, Davies MN, DeBalsi KL, Ilkayeva OR, Stevens RD, Kheterpal I, Zhang J, Covington JD, Bajpeyi S, Ravussin E, Kraus W, Koves TR, Mynatt RL (2012) Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab 15(5):764–777
95. Son NH, Yu S, Tuinei J, Arai K, Hamai H, Homma S, Shulman GI, Abel ED, Goldberg IJ (2010) PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J Clin Investig 120(10):3443–3454
96. Milne GL, Musiek ES, Morrow JD (2005) F2-isoprostanes as markers of oxidative stress in vivo: an overview. Biomark Biochem Indic Expo Response Susceptibility Chem 10(1):S10–S23
97. Morrow JD (2005) Quantification of isoprostanes as indices of oxidant stress and the risk of atherosclerosis in humans. Arterioscler Thromb Vasc Biol 25(2):279–286
98. Stadler K, Bonini MG, Dallas S, Jiang J, Radi R, Mason RP, Kadiiska MB (2008) Involvement of inducible nitric oxide synthase in hydroxyl radical-mediated lipid peroxidation in streptozotocin-induced diabetes. Free Radic Biol Med 45(6):866–874
99. Bohle A, Wehrmann M, Bogenschütz O, Batz C, Müller CA, Müller GA (1991) The pathogenesis of chronic renal failure in diabetic nephropathy. Investigation of 488 cases of diabetic glomerulosclerosis. Pathol Res Pract 187(2–3):251–259
100. Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K (1993) The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21(5):480–485
101. Bending JJ, Lobo-Yeo A, Vergani D, Viberti GC (1988) Proteinuria and activated T-lymphocytes in diabetic nephropathy. Diabetes 37(5):507–511
102. Moriya R, Manivel JC, Mauer M (2004) Juxtaglomerular apparatus T-cell infiltration affects glomerular structure in Type 1 diabetic patients. Diabetologia 47(1):82–88
103. Fardon NJ, Wilkinson R, Thomas TH (2002) Abnormalities in primary granule exocytosis in neutrophils from Type I diabetic patients with nephropathy. Clin Sci 102(1):69–75
104. Takahashi T, Hato F, Yamane T, Inaba M, Okuno Y, Nishizawa Y, Kitagawa S (2000) Increased spontaneous adherence of neutrophils from type 2 diabetic patients with overt proteinuria: possible role of the progression of diabetic nephropathy. Diabetes Care 23(3):417–418
105. Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ (2003) Adoptive transfer studies demonstrate that macrophages can induce proteinuria and mesangial cell proliferation. Kidney Int 63(1):83–95
106. Chakravorty SJ, Cockwell P, Girdlestone J, Brooks CJ, Savage CO (2002) Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion. Clin Exp Immunol 129(1):150–159
107. Cockwell P, Calderwood JW, Brooks CJ, Chakravorty SJ, Savage CO (2002) Chemoattraction of T cells expressing CCR5, CXCR3 and CX3CR1 by proximal tubular epithelial cell chemokines. Nephrol Dial Transplant 17(5):734–744
108. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, Yoshioka N, Imai H, Kakei M, Ito S (2003) Association of monocyte chemoattractant protein-1 with renal tubular damage in diabetic nephropathy. J Diabetes Complicat 17(1):11–15
109. Tesch GH, Schwarting A, Kinoshita K, Lan HY, Rollins BJ, Kelley VR (1999) Monocyte chemoattractant protein-1 promotes macrophage-mediated tubular injury, but not glomerular injury, in nephrotoxic serum nephritis. J Clin Investig 103(1):73–80
110. Yu XQ, Nikolic-Paterson DJ, Mu W, Giachelli CM, Atkins RC, Johnson RJ, Lan HY (1998) A functional role for osteopontin in experimental crescentic glomerulonephritis in the rat. Proc Assoc Am Physicians 110(1):50–64
111. Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, Shikata Y, Miyatake N, Miyasaka M, Makino H (1997) Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 46(12):2075–2081
112. Matsui H, Suzuki M, Tsukuda R, Iida K, Miyasaka M, Ikeda H (1996) Expression of ICAM-1 on glomeruli is associated with progression of diabetic nephropathy in a genetically obese diabetic rat, Wistar fatty. Diabetes Res Clin Pract 32(1–2):1–9
113. Coimbra TM, Janssen U, Gröne HJ, Ostendorf T, Kunter U, Schmidt H, Brabant G, Floege J (2000) Early events leading to renal injury in obese Zucker (fatty) rats with type II diabetes. Kidney Int 57(1):167–182
114. Park CW, Kim JH, Lee JH, Kim YS, Ahn HJ, Shin YS, Kim SY, Choi EJ, Chang YS, Bang BK (2000) High glucose-induced intercellular adhesion molecule-1 (ICAM-1) expression through an osmotic effect in rat mesangial cells is PKC-NF-kappa B-dependent. Diabetologia 43(12):1544–1553
115. Okouchi M, Okayama N, Shimizu M, Omi H, Fukutomi T, Itoh M (2002) High insulin exacerbates neutrophil-endothelial cell adhesion through endothelial surface expression of intercellular adhesion molecule-1 via activation of protein kinase C and mitogen-activated protein kinase. Diabetologia 45(4):556–559
116. Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkins RC, Kawaguchi H, Ito K (1999) Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. Kidney Int Suppl 71:S47–S50
117. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R (2002) Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105(7):816–822
118. Onozato ML, Tojo A, Goto A, Fujita T (2004) Radical scavenging effect of gliclazide in diabetic rats fed with a high cholesterol diet. Kidney Int 65(3):951–960
119. Ueda A, Ishigatsubo Y, Okubo T, Yoshimura T (1997) Transcriptional regulation of the human monocyte chemoattractant protein-1 gene. Cooperation of two NF-kappaB sites and NF-kappaB/Rel subunit specificity. J Biol Chem 272(49):31092–31099
120. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, Hong M, Luther T, Henle T, Klöting I, Morcos M, Hofmann M, Tritschler H, Weigle B, Kasper M, Smith M, Perry G, Schmidt AM, Stern DM, Häring HU, Schleicher E, Nawroth PP (2001) Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes 50(12):2792–2808
121. Ihm CG, Park JK, Hong SP, Lee TW, Cho BS, Kim MJ, Cha DR, Ha H (1998) A high glucose concentration stimulates the expression of monocyte chemotactic peptide 1 in human mesangial cells. Nephron 79(1):33–37
122. Wada T, Yokoyama H, Furuichi K, Kobayashi KI, Harada K, Naruto M, Su SB, Akiyama M, Mukaida N, Matsushima K (1996) Intervention of crescentic glomerulonephritis by antibodies to monocyte chemotactic and activating factor (MCAF/MCP-1). FASEB J 10(12):1418–1425
123. Kikuchi Y, Ikee R, Hemmi N, Hyodo N, Saigusa T, Namikoshi T, Yamada M, Suzuki S, Miura S (2004) Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-induced diabetic kidneys. Nephron Exp Nephrol 97(1):e17–e25
124. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR, Ouedraogo R, Hough K, McCue P, Chan L, Falkner B, Goldstein BJ (2008) Adiponectin regulates albuminuria and podocyte function in mice. J Clin Investig 118(5):1645–1656
125. Hallows KR, Mount PF, Pastor-Soler NM, Power DA (2010) Role of the energy sensor AMP-activated protein kinase in renal physiology and disease. Am J Physiol Ren Physiol 298(5):F1067–F1077
126. Cammisotto PG, Londono I, Gingras D, Bendayan M (2008) Control of glycogen synthase through ADIPOR1-AMPK pathway in renal distal tubules of normal and diabetic rats. Am J Physiol Ren Physiol 294(4):F881–F889
127. Guo Z, Zhao Z (2007) Effect of N-acetylcysteine on plasma adiponectin and renal adiponectin receptors in streptozotocin-induced diabetic rats. Eur J Pharmacol 558(1–3):208–213
128. Lee MJ, Feliers D, Mariappan MM, Sataranatarajan K, Mahimainathan L, Musi N, Foretz M, Viollet B, Weinberg JM, Choudhury GG, Kasinath BS (2007) A role for AMP-activated protein kinase in diabetes-induced renal hypertrophy. Am J Physiol Ren Physiol 292(2):F617–F627
129. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Tesch GH (2005) Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16(6):1711–1722
130. Amann B, Tinzmann R, Angelkort B (2003) ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1. Diabetes Care 26(8):2421–2425
131. Nikolic-Paterson DJ, Atkins RC (2001) The role of macrophages in glomerulonephritis. Nephrol Dial Transplant 16(Suppl 5):3–7
132. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH (2004) Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 19(12):2987–2996
133. Korpinen E, Groop PH, Fagerudd JA, Teppo AM, Akerblom HK, Vaarala O (2001) Increased secretion of TGF-beta1 by peripheral blood mononuclear cells from patients with Type 1 diabetes mellitus with diabetic nephropathy. Diabet Med 18(2):121–125
134. Stahl RA, Thaiss F, Haberstroh U, Kahf S, Shaw A, Schoeppe W (1990) Cyclooxygenase inhibition enhances rat interleukin 1 beta-induced growth of rat mesangial cells in culture. Am J Physiol 259(3 Pt 2):F419–F424
135. Floege J, Topley N, Hoppe J, Barrett TB, Resch K (1991) Mitogenic effect of platelet-derived growth factor in human glomerular mesangial cells: modulation and/or suppression by inflammatory cytokines. Clin Exp Immunol 86(2):334–341
136. Vesey DA, Cheung C, Cuttle L, Endre Z, Gobe G, Johnson DW (2002) Interleukin-1beta stimulates human renal fibroblast proliferation and matrix protein production by means of a transforming growth factor-beta-dependent mechanism. J Lab Clin Med 140(5):342–350
137. Musante L, Tataruch DE, Holthofer H (2014) Use and isolation of urinary exosomes as biomarkers for diabetic nephropathy. Front Endocrinol 5:149
138. van der Pol E, Böing AN, Harrison P, Sturk A, Nieuwland R (2012) Classification, functions, and clinical relevance of extracellular vesicles. Pharmacol Rev 64(3):676–705
139. Wubbolts R, Leckie RS, Veenhuizen PT, Schwarzmann G, Möbius W, Hoernschemeyer J, Slot JW, Geuze HJ, Stoorvogel W (2003) Proteomic and biochemical analyses of human B cell-derived exosomes. Potential implications for their function and multivesicular body formation. J Biol Chem 278(13):10963–10972
140. Clayton A, Court J, Navabi H, Adams M, Mason MD, Hobot JA, Newman GR, Jasani B (2001) Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. J Immunol Methods 247(1–2):163–174
141. Théry C, Ostrowski M, Segura E (2009) Membrane vesicles as conveyors of immune responses. Nat Rev Immunol 9(8):581–593
142. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, Marmé F, Umansky L, Umansky V, Eigenbrod T, Sammar M, Altevogt P (2013) Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. J Biol Chem 288(51):36691–36702
143. Danesh A, Inglis HC, Jackman RP, Wu S, Deng X, Muench MO, Heitman JW, Norris PJ (2014) Exosomes from red blood cell units bind to monocytes and induce proinflammatory cytokines, boosting T-cell responses in vitro. Blood 123(5):687–696
144. Chen GY, Nuñez G (2010) Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 10(12):826–837
145. Feng B, Chen Y, Luo Y, Chen M, Li X, Ni Y (2010) Circulating level of microparticles and their correlation with arterial elasticity and endothelium-dependent dilation in patients with type 2 diabetes mellitus. Atherosclerosis 208(1):264–269
146. Tramontano AF, Lyubarova R, Tsiakos J, Palaia T, Deleon JR, Ragolia L (2010) Circulating endothelial microparticles in diabetes mellitus. Mediat Inflamm 2010:250476
147. Omoto S, Nomura S, Shouzu A, Hayakawa T, Shimizu H, Miyake Y, Yonemoto T, Nishikawa M, Fukuhara S, Inada M (1999) Significance of platelet-derived microparticles and activated platelets in diabetic nephropathy. Nephron 81(3):271–277
148. Brodsky SV, Zhang F, Nasjletti A, Goligorsky MS (2004) Endothelium-derived microparticles impair endothelial function in vitro. Am J Physiol Heart Circ Physiol 286(5):H1910–H1915
149. Yang C, Mwaikambo BR, Zhu T, Gagnon C, Lafleur J, Seshadri S, Lachapelle P, Lavoie JC, Chemtob S, Hardy P (2008) Lymphocytic microparticles inhibit angiogenesis by stimulating oxidative stress and negatively regulating VEGF-induced pathways. Am J Physiol Regul Integr Comp Physiol 294(2):R467–R476
150. Eldh M, Ekström K, Valadi H, Sjöstrand M, Olsson B, Jernås M, Lötvall J (2010) Exosomes communicate protective messages during oxidative stress; possible role of exosomal shuttle RNA. PLoS One 5(12):e15353
151. Gildea JJ, Seaton JE, Victor KG, Reyes CM, Wang DB, Pettigrew AC, Courtner CE, Shah N, Tran HT, Van Sciver RE, Carlson JM, Felder RA (2014) Exosomal transfer from human renal proximal tubule cells to distal tubule and collecting duct cells. Clin Biochem 47(15):89–94
152. Watanabe A, Tomino Y, Yokoyama K, Koide H (1993) Production of hydrogen peroxide by neutrophilic polymorphonuclear leukocytes in patients with diabetic nephropathy. J Clin Lab Anal 7(4):209–213
153. Spanu S, van Roeyen CR, Denecke B, Floege J, Mühlfeld AS (2014) Urinary exosomes: a novel means to non-invasively assess changes in renal gene and protein expression. PLoS One 9(10):e109631
154. Zubiri I, Posada-Ayala M, Sanz-Maroto A, Calvo E, Martin-Lorenzo M, Gonzalez-Calero L, de la Cuesta F, Lopez JA, Fernandez-Fernandez B, Ortiz A, Vivanco F, Alvarez-Llamas G (2014) Diabetic nephropathy induces changes in the proteome of human urinary exosomes as revealed by label-free comparative analysis. J Proteomics 96:92–102
155. Barutta F, Tricarico M, Corbelli A, Annaratone L, Pinach S, Grimaldi S, Bruno G, Cimino D, Taverna D, Deregibus MC, Rastaldi MP, Perin PC, Gruden G (2013) Urinary exosomal microRNAs in incipient diabetic nephropathy. PLoS One 8(11):e73798
156. Pryor WA (1986) Oxy-radicals and related species: their formation, lifetimes and reactions. Annu Rev Physiol 48:657–667
157. Furukawa M, Gohda T, Tanimoto M, Tomino Y (2013) Pathogenesis and novel treatment from the mouse model of type 2 diabetic nephropathy. Sci World J 2013:928197
158. Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M (2009) Recent advances in pharmacotherapy for diabetic nephropathy: current perspectives and future directions. Pharmacol Res 60(1):24–32
159. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329(20):1456–1462
160. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH (2000) Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 57(2):601–606
161. Hong SW, Isono M, Chen S, Iglesias-De La Cruz MC, Han DC, Ziyadeh FN (2001) Increased glomerular and tubular expression of transforming growth factor-β1, its type II receptor, and activation of the smad signaling pathway in the db/db mouse. Am J Pathol 158(5):1653–1663
162. Ha H, Kim KH (1992) Amelioration of diabetic microalbuminuria and lipid peroxidation by captopril. Yonsei Med J 33(3):217–223
163. Katayama S, Kikkawa R, Isogai S, Sasaki N, Matsuura N, Tajima N, Urakami T, Uchigata Y, Ohashi Y (2002) Effect of captopril or imidapril on the progression of diabetic nephropathy in Japanese with type 1 diabetes mellitus: a randomized controlled study (JAPAN-IDDM). Diabetes Res Clin Pract 55(2):113–121
164. Gerstein HC (2001) Diabetes and the HOPE study: implications for macrovascular and microvascular disease. Int J Clin Pract Suppl 117:8–12
165. McLennan SV, Kelly DJ, Cox AJ, Cao Z, Lyons JG, Yue DK, Gilbert RE (2002) Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the expression and activities of matrix metalloproteinases. Diabetologia 45(2):268–275
166. Lin H, Huang S, Mi X, Sha Z (2003) Effects of cilazapril on the expression of vascular endothelial growth factor and intercellular adhesion molecule-1 in diabetic rat glomeruli. Sichuan Da Xue Xue Bao Yi Xue Ban 34(4):694–697
167. Lv Y, Dong J, Niu X, Liu X (2005) Renoprotective effect of benazepril on diabetic nephropathy mediated by P42/44MAPK. J Huazhong Univ Sci Technol Med Sci 25(1):32–35
168. Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, Shahinfar S, Gleim GW, Weir MR, Brenner BM, de Zeeuw D (2007) Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 18(5):1540–1546
169. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I, Collaborative Study Group (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345(12):851–860
170. Hunsicker LG (2004) Emerging trends for prevention and treatment of diabetic nephropathy: blockade of the RAAS and BP control. J ManagCare Pharm 10((5 Suppl A)):S12–S17
171. Pugsley MK (2005) The angiotensin-II (AT-II) receptor blocker olmesartan reduces renal damage in animal models of hypertension and diabetes. Proc West Pharmacol Soc 48:35–38
172. Liao J, Kobayashi M, Kanamuru Y, Nakamura S, Makita Y, Funabiki K, Horikoshi S, Tomino Y (2003) Effects of candesartan, an angiotensin II type 1 receptor blocker, on diabetic nephropathy in KK/Ta mice. J Nephrol 16(6):841–849
173. Moranne O, Bakris G, Fafin C, Favre G, Pradier C, Esnault VL (2013) Determinants and changes associated with aldosterone breakthrough after angiotensin II receptor blockade in patients with type 2 diabetes with overt nephropathy. Clin J Am Soc Nephrol 8(10):1694–1701
174. Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3(9):486–492
175. Sato A, Hayashi K, Naruse M, Saruta T (2003) Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 41(1):64–68
176. Horita Y, Taura K, Taguchi T, Furusu A, Kohno S (2006) Aldosterone breakthrough during therapy with angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in proteinuric patients with immunoglobulin A nephropathy. Nephrology 11(5):462–466
177. Greene EL, Kren S, Hostetter TH (1996) Role of aldosterone in the remnant kidney model in the rat. J Clin Investig 98(4):1063–1068
178. Roscioni SS, Heerspink HJ, de Zeeuw D (2014) The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 10(2):77–87
179. Gentile G, Remuzzi G, Ruggenenti P (2015) Dual renin-angiotensin system blockade for nephroprotection: still under scrutiny. Nephron 129(1):39–41
180. Fried LF, Emanuele N, Zhang JH, Brophy M, Conner TA, Duckworth W, Leehey DJ, McCullough PA, O’Connor T, Palevsky PM, Reilly RF, Seliger SL, Warren SR, Watnick S, Peduzzi P, Guarino P, VA NEPHRON-D Investigators (2013) Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med 369(20):1892–1903
181. Tsuchida K, Makita Z, Yamagishi S, Atsumi T, Miyoshi H, Obara S, Ishida M, Ishikawa S, Yasumura K, Koike T (1999) Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195. Diabetologia 42(5):579–588
182. Forbes JM, Soulis T, Thallas V, Panagiotopoulos S, Long DM, Vasan S, Wagle D, Jerums G, Cooper ME (2001) Renoprotective effects of a novel inhibitor of advanced glycation. Diabetologia 44(1):108–114
183. Thallas-Bonke V, Lindschau C, Rizkalla B, Bach LA, Boner G, Meier M, Haller H, Cooper ME, Forbes JM (2004) Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-alpha-dependent pathway. Diabetes 53(11):2921–2930
184. Twigg SM, Cao Z, MCLennan SV, Burns WC, Brammar G, Forbes JM, Cooper ME (2002) Renal connective tissue growth factor induction in experimental diabetes is prevented by aminoguanidine. Endocrinology 143(12):4907–4915
185. Izuhara Y, Nangaku M, Takizawa S, Takahashi S, Shao J, Oishi H, Kobayashi H, van Ypersele de Strihou CY, Miyata T (2008) A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models. Nephrol Dial Transplant 23(2):497–509
186. Figarola JL, Loera S, Weng Y, Shanmugam N, Natarajan R, Rahbar S (2008) LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat. Diabetologia 51(5):882–891
187. Hill C, Flyvbjerg A, Rasch R, Bak M, Logan A (2001) Transforming growth factor-β antibody attenuates fibrosis in the experimental diabetic rat kidney. J Endocrinol 170(3):647–651
188. Benigni A, Zoja C, Campana M, Corna D, Sangalli F, Rottoli D, Gagliardini E, Conti S, Ledbetter S, Remuzzi G (2006) Beneficial effect of TGF- β antagonism in treating diabetic nephropathy depends on when treatment is started. Nephron Exp Nephrol 104(4):e158–e168
189. Mizuno S, Nakamura T (2004) Suppressions of chronic glomerular injuries and TGF-β1 production by HGF in attenuation of murine diabetic nephropathy. Am J Physiol Ren Physiol 286(1):F134–F143
190. Jeong HS, Park KK, Park KK, Kim SP, Choi IJ, Lee IK, Kim HC (2004) Effect of antisense TGF-β1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney. J Korean Med Sci 19(3):374–383
191. Russo LM, del Re E, Brown D, Lin HY (2007) Evidence for a role of transforming growth factor (TGF)-β1 in the induction of postglomerular albuminuria in diabetic nephropathy. Amelioration by soluble (TGF)-β1 type II receptor. Diabetes 56(2):380–388
192. Lee HS (2013) Pathogenic role of TGF-β in diabetic nephropathy. J Diabetes Metab S9:008. doi:10.4172/2155-6156.S9-008
193. Ma X, Ding J, Min H, Wen Y, Gao Q (2013) Protective role of low-dose TGF-β1 in early diabetic nephropathy induced by streptozotocin. Int Immunopharmacol 17(3):752–758
194. Wahab NA, Schaefer L, Weston BS, Yiannikouris O, Wright A, Babelova A, Schaefer R, Mason RM (2005) Glomerular expression of thrombospondin-1, transforming growth factor beta and connective tissue growth factor at different stages of diabetic nephropathy and their interdependent roles in mesangial response to diabetic stimuli. Diabetologia 48(12):2650–2660
195. Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, Aten J, Höppener JW, Goldschmeding R (2006) Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Ren Physiol 290(6):F1344–F1354
196. Keil A, Blom IE, Goldschmeding R, Rupprecht HD (2002) Nitric oxide down-regulates connective tissue growth factor in rat mesangial cells. Kidney Int 62(2):401–411
197. Hishikawa K, Oemar BS, Nakaki T (2001) Static pressure regulates connective tissue growth factor expression in human mesangial cells. J Biol Chem 276(20):16797–16803
198. Wahab NA, Weston BS, Mason RM (2005) Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 307(2):305–314
199. Han KH, Kang YS, Han SY, Jee YH, Lee MH, Han JY, Kim HK, Kim YS, Cha DR (2006) Spironolactone ameliorates renal injury and connective tissue growth factor expression in type II diabetic rats. Kidney Int 70(1):111–120
200. Sohn M, Tan Y, Wang B, Klein RL, Trojanowska M, Jaffa AA (2006) Mechanisms of low-density lipoprotein-induced expression of connective tissue growth factor in human aortic endothelial cells. Am J Physiol Heart Circ Physiol 290(4):H1624–H1634
201. Finckenberg P, Inkinen K, Ahonen J, Merasto S, Louhelainen M, Vapaatalo H, Müller D, Ganten D, Luft F, Mervaala E (2003) Angiotensin II induces connective tissue growth factor gene expression via calcineurin-dependent pathways. Am J Pathol 163(1):355–366
202. Rodriguez-Vita J, Ruiz-Ortega M, Rupérez M, Esteban V, Sanchez-López E, Plaza JJ, Egido J (2005) Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 97(2):125–134
203. Rodríguez-Vita J, Sánchez-López E, Esteban V, Rupérez M, Egido J, Ruiz-Ortega M (2005) Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation 111(19):2509–2517
204. Igarashi A, Okochi H, Bradham DM, Grotendorst GR (1993) Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4(6):637–645
205. Graness A, Cicha I, Goppelt-Struebe M (2006) Contribution of Src-FAK signaling to the induction of connective tissue growth factor in renal fibroblasts. Kidney Int 69(8):1341–1349
206. Lam S, van der Geest RN, Verhagen NA, van Nieuwenhoven FA, Blom IE, Aten J, Goldschmeding R, Daha MR, van Kooten C (2003) Connective tissue growth factor and igf-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 52(12):2975–2983
207. Burns WC, Twigg SM, Forbes JM, Pete J, Tikellis C, Thallas-Bonke V, Thomas MC, Cooper ME, Kantharidis P (2006) Connective tissue growth factor plays an important role in advanced glycation end product-induced tubular epithelial-to-mesenchymal transition: implications for diabetic renal disease. J Am Soc Nephrol 17(9):2484–2494
208. Kobayashi T, Inoue T, Okada H, Kikuta T, Kanno Y, Nishida T, Takigawa M, Sugaya T, Suzuki H (2005) Connective tissue growth factor mediates the profibrotic effects of transforming growth factor-beta produced by tubular epithelial cells in response to high glucose. Clin Exp Nephrol 9(2):114–121
209. Twigg SM, Joly AH, Chen MM, Tsubaki J, Kim HS, Hwa V, Oh Y, Rosenfeld RG (2002) Connective tissue growth factor/IGF-binding protein-related protein-2 is a mediator in the induction of fibronectin by advanced glycosylation end-products in human dermal fibroblasts. Endocrinology 143(4):1260–1269
210. Chaqour B, Goppelt-Struebe M (2006) Mechanical regulation of the Cyr61/CCN1 and CTGF/CCN2 proteins. FEBS J 273(16):3639–3649
211. Liu BC, Sun J, Chen Q, Ma KL, Ruan XZ, Phillips AO (2003) Role of connective tissue growth factor in mediating hypertrophy of human proximal tubular cells induced by angiotensin II. Am J Nephrol 23(6):429–437
212. Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, Goldschmeding R, Parving HH (2005) Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int 67(6):2325–2329
213. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH (2004) Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Ren Physiol 287(6):F1223–F1232
214. Adler SG, Schwartz S, Williams ME, Arauz-Pacheco C, Bolton WK, Lee T, Li D, Neff TB, Urquilla PR, Sewell KL (2010) Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 5(8):1420–1428
215. Tuttle KR, Anderson PW (2003) A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C beta inhibition. Am J Kidney Dis 42(3):456–465
216. Kelly DJ, Chanty A, Gow RM, Zhang Y, Gilbert RE (2005) Protein kinase C beta inhibition attenuates osteopontin expression, macrophage recruitment, and tubulointerstitial injury in advanced experimental diabetic nephropathy. J Am Soc Nephrol 16(6):1654–1660
217. Kelly DJ, Buck D, Cox AJ, Zhang Y, Gilbert RE (2007) Effects on protein kinase C-beta inhibition on glomerular vascular endothelial growth factor expression and endothelial cells in advanced experimental diabetic nephropathy. Am J Physiol Ren Physiol 293(2):F565–F574
218. Schwartz S, Raskin P, Fonseca V, Graveline JF (1998) Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 338(13):861–866
219. Imano E, Kanda T, Nakatani Y, Nishida T, Arai K, Motomura M, Kajimoto Y, Yamasaki Y, Hori M (1998) Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21(12):2135–2139
220. Fujii M, Takemura R, Yamaguchi M, Hasegawa G, Shigeta H, Nakano K, Kondo M (1997) Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 46(9):981–983
221. McFarlane SI, Muniyappa R, Francisco R, Sowers JR (2002) Clinical review 145: pleiotropic effects of statins: lipid reduction and beyond. J Clin Endocrinol Metab 87(4):1451–1458
222. Endres M, Laufs U (2004) Effects of statins on endothelium and signaling mechanisms. Stroke 35(11 Suppl 1):2708–2711
223. Dubey VK, Patil CR, Kamble SM, Tidke PS, Patil KR, Maniya PJ, Jadhav RB, Patil SP (2013) Oleanolic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley rats. J Pharmacol Pharmacother. 4(1):47–52
224. Jain AB, Jain VA (2012) Vitamin E, its beneficial role in diabetes mellitus (DM) and its complications. J Clin Diagn Res 6(10):1624–1628